0.1373
3.47%
+0.0046
After Hours:
.1352
-0.0021
-1.53%
Kintara Therapeutics Inc stock is currently priced at $0.1373, with a 24-hour trading volume of 5.82M.
It has seen a +3.47% increased in the last 24 hours and a +50.05% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.129 pivot point. If it approaches the $0.147 resistance level, significant changes may occur.
Previous Close:
$0.1327
Open:
$0.1306
24h Volume:
5.82M
Market Cap:
$5.36M
Revenue:
-
Net Income/Loss:
$-10.58M
P/E Ratio:
-0.0145
EPS:
-9.49
Net Cash Flow:
$-6.79M
1W Performance:
+32.27%
1M Performance:
+50.05%
6M Performance:
-96.83%
1Y Performance:
-95.71%
Kintara Therapeutics Inc Stock (KTRA) Company Profile
Name
Kintara Therapeutics Inc
Sector
Industry
Phone
858 350 4364
Address
9920 Pacific Heights Blvd, Suite 150, San Diego
Kintara Therapeutics Inc Stock (KTRA) Latest News
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Zacks Investment Research
3 Steps to Building a Winning Penny Stocks Trading Plan
PennyStocks
Nasdaq Gains 75 Points; Acuity Brands Posts Upbeat Earnings
Benzinga
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Kintara Therapeutics Inc Stock (KTRA) Financials Data
Kintara Therapeutics Inc (KTRA) Net Income 2024
KTRA net income (TTM) was -$10.58 million for the quarter ending December 31, 2023, a +43.86% increase year-over-year.
Kintara Therapeutics Inc (KTRA) Cash Flow 2024
KTRA recorded a free cash flow (TTM) of -$6.79 million for the quarter ending December 31, 2023, a +64.23% increase year-over-year.
Kintara Therapeutics Inc (KTRA) Earnings per Share 2024
KTRA earnings per share (TTM) was -$5.96 for the quarter ending December 31, 2023, a +58.47% growth year-over-year.
About Kintara Therapeutics Inc
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):